ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions
View by Date

Monday, November 6, 2017

9:00AM-11:00AM
Abstract Number: 1558
Changes in Blood Pressure with TNF Inhibitors for Psoriatic Arthritis
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II
9:00AM-11:00AM
Abstract Number: 1627
Changes in Heart Rate Variability Reflect Changes in Clinical Status and Patient Reported Outcomes in Systemic Lupus Erythematosus: A Longitudinal Analysis
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities
9:00AM-11:00AM
Abstract Number: 1467
Changes in the Immune Response of RA Patients Induced By 1 Year of Tocilizumab
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports
9:00AM-11:00AM
Abstract Number: 1309
Characteristics and Outcomes of Prospectively Reported Pregnancies Exposed to Certolizumab Pegol from a Safety Database
Reproductive Issues in Rheumatic Disorders Poster
9:00AM-11:00AM
Abstract Number: 1525
Characteristics and Treatment Patterns Among Patients with Psoriatic Arthritis Initiating Subcutaneously Administered Biologics: Descriptive Analyses from a US Claims Database
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II
9:00AM-11:00AM
Abstract Number: 1493
Characteristics of Korean Primary Sjogren’s Syndrome and Comparison of 3 Different Classification Criteria for Primary Sjogren’s Syndrome: Data from Korean Kiss Cohort
Sjögren's Syndrome Poster II: Clinical Research
9:00AM-11:00AM
Abstract Number: 1419
Characteristics of Patients with Early Rheumatoid Arthritis Who Have a Delayed Response to Treatment with Methotrexate in Monotherapy or in Combination with Adalimumab
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports
9:00AM-11:00AM
Abstract Number: 1382
Characteristics of Patients with Rheumatoid Arthritis and Atlanto-Axial Pannus
Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures
9:00AM-11:00AM
Abstract Number: 1064
Characterization of Human Tolerogenic Dendritic Cells Generated with Protein Kinase C Inhibitor and Induction from Patients with Autoimmune Diseases
Innate Immunity and Rheumatic Disease Poster II
9:00AM-11:00AM
Abstract Number: 1215
Chest Radiography As a Screening Tool to Detect Fragile Spine Fractures
Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster II
9:00AM-11:00AM
Abstract Number: 1754
Childhood- Vs. Adult-Onset ANCA-Associated Vasculitides: A Nested, Matched Case–Control Study from the French Vasculitis Study Group Registry
Vasculitis Poster II: ANCA-Associated Vasculitis
9:00AM-11:00AM
Abstract Number: 1626
Childhood-Onset Predicts Increased Steroid-Related Damage Among Adults with Systemic Lupus Erythematosus
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities
9:00AM-11:00AM
Abstract Number: 1251
Chinese Patient Reported Index with Rheumatoid Arthritis (CPRI-RA): Reliability, Validity and Agreement with DAS28 and HAQ
Patient Outcomes, Preferences, and Attitudes Poster II
9:00AM-11:00AM
Abstract Number: 1584
Chlamydia-Infected Macrophages: “Trojan Horses” for Dissemination of IL-23 and TNF-Mediated Inflammation in SKG Mouse Reactive Arthritis
Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster II
9:00AM-11:00AM
Abstract Number: 1206
Chondroitin Sulfate Reduces Pain and Improves Function in Knee Osteoarthritis Significantly Better Than Placebo, Independently of the Definition of Responders
Osteoarthritis – Clinical Aspects Poster I: Clinical Trials and Interventions
  • «Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 65
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology